ANI Pharmaceuticals, Inc. ANIP

Company Overview

ANI Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company operates primarily in the pharmaceutical manufacturing and specialty therapeutics industries, with a focus on rare disease treatments, corticosteroids, oncology-related products, and complex generics. ANI generates revenue through sales of branded pharmaceuticals, generic drugs, contract manufacturing, royalties, and product licensing arrangements. Its portfolio includes both internally developed products and assets acquired through strategic transactions.

The company’s core business has evolved from a traditional generic pharmaceutical manufacturer into a diversified specialty pharmaceutical platform emphasizing higher-margin branded therapies and rare disease products. A major strategic shift occurred following the acquisition of Novitium Pharma LLC in 2021 and the acquisition of Alimera Sciences, Inc. in 2024, which expanded ANI’s capabilities in complex formulations and ophthalmology. ANI positions itself through vertically integrated manufacturing capabilities, regulatory expertise in difficult-to-manufacture products, and a portfolio that includes products with limited competition or niche therapeutic applications.